Nuclear overexpression of the E2F3 transcription factor in human lung cancer

Colin S Cooper; Andrew G Nicholson; Christopher Foster; Andrew Dodson; Sandra Edwards; Anne Fletcher; Toby Roe; Jeremy Clark; Anupam Joshi; Andrew Norman; Andrew Feber; Dongmei Lin; Yanning Gao; Janet Shipley; Shu-Jun Cheng

doi:10.1016/j.lungcan.2006.07.005

Nuclear overexpression of the E2F3 transcription factor in human lung cancer

Colin S Cooper, Andrew G Nicholson, Christopher Foster, Andrew Dodson, Sandra Edwards, Anne Fletcher, Toby Roe, Jeremy Clark, Anupam Joshi, Andrew Norman, Andrew Feber, Dongmei Lin, Yanning Gao, Janet Shipley, Shu-Jun Cheng

Research output: Contribution to journal › Article › peer-review

81 Citations (Scopus)

Abstract

The E2F3 transcription factor has an established role in controlling cell cycle progression. In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer. We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development. Since small cell lung cancers (SCLC) have one of the highest reported frequencies of functional abnormalities in the pRB protein (90%) of any human cancer, we wish to assess to what extent E2F3 would be overexpressed in this and other classes of human lung cancer.

Original language	English
Pages (from-to)	155-62
Number of pages	8
Journal	Lung Cancer
Volume	54
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2006.07.005
Publication status	Published - Nov 2006

Keywords

Adenocarcinoma
Carcinoid Tumor
Carcinoma, Neuroendocrine
Carcinoma, Small Cell
Carcinoma, Squamous Cell
Cell Nucleus
E2F3 Transcription Factor
Gene Expression Regulation, Neoplastic
Genes, Retinoblastoma
Humans
Immunohistochemistry
Lung Neoplasms
Oligonucleotide Array Sequence Analysis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.lungcan.2006.07.005

Cite this

@article{9ba8edacb46345378c87004d9395d52b,

title = "Nuclear overexpression of the E2F3 transcription factor in human lung cancer",

abstract = "The E2F3 transcription factor has an established role in controlling cell cycle progression. In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer. We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development. Since small cell lung cancers (SCLC) have one of the highest reported frequencies of functional abnormalities in the pRB protein (90%) of any human cancer, we wish to assess to what extent E2F3 would be overexpressed in this and other classes of human lung cancer.",

keywords = "Adenocarcinoma, Carcinoid Tumor, Carcinoma, Neuroendocrine, Carcinoma, Small Cell, Carcinoma, Squamous Cell, Cell Nucleus, E2F3 Transcription Factor, Gene Expression Regulation, Neoplastic, Genes, Retinoblastoma, Humans, Immunohistochemistry, Lung Neoplasms, Oligonucleotide Array Sequence Analysis",

author = "Cooper, {Colin S} and Nicholson, {Andrew G} and Christopher Foster and Andrew Dodson and Sandra Edwards and Anne Fletcher and Toby Roe and Jeremy Clark and Anupam Joshi and Andrew Norman and Andrew Feber and Dongmei Lin and Yanning Gao and Janet Shipley and Shu-Jun Cheng",

year = "2006",

month = nov,

doi = "10.1016/j.lungcan.2006.07.005",

language = "English",

volume = "54",

pages = "155--62",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Nuclear overexpression of the E2F3 transcription factor in human lung cancer

AU - Cooper, Colin S

AU - Nicholson, Andrew G

AU - Foster, Christopher

AU - Dodson, Andrew

AU - Edwards, Sandra

AU - Fletcher, Anne

AU - Roe, Toby

AU - Clark, Jeremy

AU - Joshi, Anupam

AU - Norman, Andrew

AU - Feber, Andrew

AU - Lin, Dongmei

AU - Gao, Yanning

AU - Shipley, Janet

AU - Cheng, Shu-Jun

PY - 2006/11

Y1 - 2006/11

N2 - The E2F3 transcription factor has an established role in controlling cell cycle progression. In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer. We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development. Since small cell lung cancers (SCLC) have one of the highest reported frequencies of functional abnormalities in the pRB protein (90%) of any human cancer, we wish to assess to what extent E2F3 would be overexpressed in this and other classes of human lung cancer.

AB - The E2F3 transcription factor has an established role in controlling cell cycle progression. In previous studies we have provided evidence that nuclear E2F3 overexpression represents a mechanism that drives the development of human bladder cancer and that determines aggressiveness in human prostate cancer. We have proposed a model in which E2F3 overexpression co-operates with removal of the E2F inhibitor pRB to facilitate cancer development. Since small cell lung cancers (SCLC) have one of the highest reported frequencies of functional abnormalities in the pRB protein (90%) of any human cancer, we wish to assess to what extent E2F3 would be overexpressed in this and other classes of human lung cancer.

KW - Adenocarcinoma

KW - Carcinoid Tumor

KW - Carcinoma, Neuroendocrine

KW - Carcinoma, Small Cell

KW - Carcinoma, Squamous Cell

KW - Cell Nucleus

KW - E2F3 Transcription Factor

KW - Gene Expression Regulation, Neoplastic

KW - Genes, Retinoblastoma

KW - Humans

KW - Immunohistochemistry

KW - Lung Neoplasms

KW - Oligonucleotide Array Sequence Analysis

U2 - 10.1016/j.lungcan.2006.07.005

DO - 10.1016/j.lungcan.2006.07.005

M3 - Article

C2 - 16938365

SN - 0169-5002

VL - 54

SP - 155

EP - 162

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -